Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron Overload

NCT02435212 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

224

Enrollment

INDUSTRY

Sponsor class

Conditions

Transfusion-dependent Anemia

Interventions

DRUG: Deferasirox granule formulation
DRUG: Deferasirox DT formulation

Sponsor

Novartis Pharmaceuticals